NIPRO CORPORATION

SOCIAL FINANCE FRAMEWORK

April 2026

1. Introduction

NIPRO CORPORATION (hereinafter referred to as the "Company") has established this Social Finance Framework (hereinafter referred to as the "Framework") as set forth below.
The Company has obtained a second party opinion from Rating and Investment Information, Inc. ("R&I") regarding the alignment of the Framework with the following principles and guidelines.

- Social Bond Principles 2025 (ICMA)
- Social Loan Principles 2025 (LMA, APLMA, LSTA)
- Social Bond Guidelines (2021 Edition, Financial Services Agency of Japan)

1) Company Overview

The NIPRO Group (hereinafter referred to as the "Group") consists of NIPRO CORPORATION, 168 consolidated subsidiaries, and 7 affiliated companies.
The Group operates three business segments: Medical-Related, Pharmaceutical-Related, and PharmaPackaging.

2) Management Philosophy

The Group's management philosophy is:

"In looking toward our future as a truly global comprehensive medical manufacturer, we believe our current and future responsibility to society is to develop innovative, value-added products and technologies that improve patient outcomes and healthcare worldwide."

Based on this philosophy, the Group adopts the following guiding principles:

- From the viewpoints of patients and users, the Medical Devices Division, Pharmaceutical Division, and PharmaPackaging Division work together as one to meet the needs of clinical settings with world-leading, innovative, safe, and defect-free products, technologies, and businesses.
- In promoting its strategies, the Group operates under the Sanpo-yoshi concept—good for the company, good for users, and good for society.
- In global expansion, the Group builds production and sales networks based on the concept of local production for local consumption, contributing to people's health around the world while ensuring a stable supply.

3) Management Policy

Since its establishment in 1954, the Company has positioned technological innovation as its core concept and has promoted business activities aimed at contributing to society.
The Group continuously develops products that respond to user needs, including the improvement of patients' quality of life (QOL) and the resolution of challenges faced in clinical settings.

The Group's basic strategy has been to respond to on-site needs through product development, enhance production capacity through improvements in manufacturing processes, and provide stable, high-quality, and cost-competitive products, thereby expanding market share and sales. By effectively leveraging proprietary technologies and management resources spanning its Medical-Related, Pharmaceutical-Related, and PharmaPackaging businesses, the Group is committed to developing highly safe and value-added products from the users' viewpoints. Even amid increasing uncertainty in the business environment, the Group aims to achieve world-leading product competitiveness and market share, evolve into a globally recognized corporate group based on local production for local consumption, and fulfill its responsibility as a comprehensive global healthcare manufacturer.

4) Materiality

Through a defined materiality identification process, the Group has identified material issues (key sustainability matters) that guide its management and business activities

Materiality identification process

- **STEP 1** Interview internal and external stakeholders to identify risks, opportunities, and impacts unique to the Nipro Group
- **STEP 2** Weight (score) the importance of the risks, opportunities, and impacts to the Nipro Group
- **STEP 3** Identify the risks, opportunities, and impacts with high scores as being material (important) to the Nipro Group

Identified materiality

Environment	■ Climate Change ■ Biodiversity and Ecosystems ■ Circular Economy
Social	■ Human Capital Management ■ Human Rights in the Value Chain ■ Data Privacy and Cyber Security ■ Patient Safety and Product Quality
Governance	■ Instillation and Establishment of Code of Conduct ■ Sustainable Value Chain ■ Prevention of Corruption and Bribery

5) Sustainability Management

The Group promotes sustainability management in order to address social issues through its business activities and has strengthened its governance structure accordingly.
The President and Representative Director serves as the person with overall responsibility for sustainability management within the Group and assumes responsibility for climate-related matters within decision-making bodies such as the Board of Directors.
In addition, the Group has appointed a Chief Sustainability Officer (CSO) to strengthen the promotion structure for sustainability management.
The CSO serves as chair of the Sustainability Committee and oversees sustainability-related initiatives across all business divisions.
The Sustainability Committee is further divided into the Environmental Committee, Social Committee, and Governance Committee, which manage and promote ESG initiatives.
The status of ESG initiatives is reported to and deliberated by the Board of Directors at least once each quarter, including discussion of strategies, KPI setting, and progress management.

Sustainability promotion system



6) Medium-Term Management Plan (FY2025–FY2027)

In May 2025, the Group announced its Medium-Term Management Plan (FY2025–FY2027). The Group will continue to place importance on users' viewpoints, pursue not only improvements to existing products but also the development of world-first products, and work toward commercialization. To promote these initiatives, the Group has established ten key policies and five specific strengthening measures.

NIPRO's 10 Key Policies

1. Increase sales prices per unit toward a Group-wide operating profit ratio of 9% or more in FY2023.
2. Increase product competitiveness for all products through improvements, expansion of product lineups, and DX. Furthermore, work forward automated production for each product, aiming for fully automated inspection and full automation for all products.
3. Promote DX in administration, logistics, and production for efficiency, productivity, and labor savings as well as reduce costs and contribute to higher operation margin.
4. Treat specialists the same as line managers with performance-based distribution through the implementation of policies 2 and 3.
5. Maintain corporate culture that provides opportunities to people exhibiting "Willingness".
6. Adopt thorough risk management measures for both natural and man-made disasters.
7. Steadily share relevant information related to the PDCA Cycle among all involved parties.
8. Adhere to "Sanpo-Yoshi" Principle based on the idea of "Good for everyone (3 parties)—the company, users, and society".
9. Promote the concept of local production for local consumption.
10. Put priorities on operating profit above sales, on full automation above operating profit, on risk management above full automation, and on compliance above risk management.

5 Specific Measures to Strengthen

1. Ensure a stable supply of dialysis products, especially dialyzers.
2. Significantly improve productivity and global sales of vascular products.
3. Strive for profitability for all products running deficits.
4. Strongly promote developed products to establish them as a business promptly.
5. Promote greater product lineup variability, systematization, and DX for all products, and enhance informational materials to bolster technology sales, aiming to enhance product competitiveness.

7) Regional Strategy

In response to increasingly diverse global markets, the Company promotes rapid adaptation to regional needs and advances local production for local consumption. Key Policy (9)

By further strengthening its global production and sales systems and enhancing localization through effective investments, the Group aims to realize stable supply and sustainable growth worldwide.



8) Purpose and Background of the Social Finance Framework

The Group contributes to improving health and quality of life worldwide through essential initiatives such as stable supply of medical devices and pharmaceuticals based on local production for local consumption.

In order to realize these initiatives through finance, the Group has established this Framework and will raise funds through social finance.

2. **Social Finance Framework**

1) Use of Proceeds

Funds raised under this Framework will be allocated to new investments in, or refinancing of existing investments in, new or existing projects that meet the eligibility criteria set forth below. Where proceeds are used for refinancing, eligible projects are those implemented within 36 months prior to the relevant social finance fundraising date.

<table>
<tr><th>Business Category</th><th>Eligibility Criteria</th><th>Relevant SDGs</th></tr>
<tr><td rowspan="3">Access to Essential Services (Health and Healthcare)</td><td>Costs related to the manufacture of antibiotics drug formulations (including capital expenditures)</td><td rowspan="2">
</td></tr>
<tr><td>Costs related to the manufacture of vaccines (including capital expenditures)</td></tr>
<tr><td>Costs related to the manufacture of medical devices necessary for dialysis and the expansion of access to dialysis treatment (including capital expenditures)</td><td>
</td></tr>
</table>

Funds raised in accordance with this Framework are intended to contribute to the resolution of social issues, and are expected to generate positive social impacts for the “Target Population” as exemplified herein.

Eligibility Criteria	Social Issue Addressed	Target Population
Costs related to the manufacture of antibiotics pharmaceutical products (including capital expenditures)	Domestic production and stable supply of antibiotics drugs essential for the prevention and treatment of infectious diseases	General public, including people in need of antibiotics pharmaceutical products
Costs related to the manufacture of vaccines (including capital expenditures)	Domestic production and stable supply of vaccines in response to emergencies such as the spread of emerging infectious diseases	General public, including people requiring measures against infectious diseases
Costs related to the manufacture of medical devices necessary for hemodialysis and the	Stable supply of essential medical devices and promotion of dialysis treatment, which are indispensable for sustaining life, improving health, and	Patients requiring hemodialysis

expansion of dialysis treatment (including capital expenditures)	enhancing quality of life for patients requiring hemodialysis	

2) Project Evaluation and Selection Process

The Corporate Planning Department within the Corporate Planning Headquarters evaluates and selects projects that meet the Eligibility Criteria, and the final decision is made upon approval by the officer in charge of finance.

In the case of projects undertaken by companies within the Company's group, the Company conducts the assessment based on the above selection process and subsequently notifies the relevant group companies of the decision.

In assessing project eligibility, due consideration is given to potential negative impacts, and confirmation is made that the following items are appropriately addressed:

- Compliance with applicable laws and regulations required by the national government and/or local authorities in the area where the project is implemented
- Adequate explanation and communication with local communities in connection with the implementation of the project
- Implementation of procurement practices, prevention of environmental pollution, consideration for the working environment, and respect for human rights, in line with the Company Group's management philosophy, environmental policy, and human rights policy

3) Management of Proceeds

Funds raised through social finance are deposited into bank accounts held in the name of the Company or the relevant Group company.

When the Company raises funds, the Corporate Planning Headquarters Accounting Department manages the proceeds, and the officer responsible for finance confirms the allocation status on an annual basis.

When Group companies raise funds, each company manages the proceeds and makes payments related to project implementation in accordance with the same procedures as those of the Company, and reports the allocation status to the Company periodically. Annual confirmation is also conducted by the officer responsible for finance.

Until allocated to eligible projects, unallocated proceeds are managed in accordance with internal regulations and are limited to highly liquid and secure financial assets.

4) Reporting

Until all proceeds have been fully allocated, the Company will disclose relevant information, within the scope of confidentiality, on its website at least once per year, regardless of the fundraising entity.

4.1) Allocation Reporting

The allocation status of proceeds, including the allocated amount and any unallocated balance, as well as the proportion allocated to new investments and refinancing, will be disclosed annually.

If any material changes occur after full allocation, such information will be disclosed in a timely manner.

4.2) Impact Reporting

Until all proceeds are redeemed or repaid, the Company will disclose impact reporting annually, within the scope of confidentiality and to the extent reasonably practicable, including output and outcome indicators related to eligible projects.

Eligibility Criteria	Output	Outcome	Impact
Costs related to the manufacture of antibiotics pharmaceutical products (including capital expenditures)	･Rate of increase/decrease in the volume of antibiotics pharmaceutical products manufactured	･Rate of increase/decrease in sales volume of antibiotics pharmaceutical products	Domestic production and stable supply of medical products
Costs related to the manufacture of vaccines (including capital expenditures)	･Production capacity of vials and/or related manufacturing facilities	･Volume of vaccines supplied	Domestic production and stable supply of medical products
Costs related to the manufacture of medical devices necessary for hemodialysis and the expansion of dialysis treatment (including capital expenditures)	･Rate of increase/decrease in the number of dialyzers manufactured ･Number of training centers	･Rate of increase/decrease in sales volume of dialyzers ･Number of users of training centers	Sustaining life, improving health, and enhancing quality of life for patients requiring hemodialysis

End